<VariationArchive RecordType="classified" VariationID="10633" VariationName="F9, EX2-8DEL" VariationType="Deletion" Accession="VCV000010633" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-19" DateCreated="2017-10-12" MostRecentSubmission="2017-10-12">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="25672" VariationID="10633">
      <GeneList>
        <Gene Symbol="F9" FullName="coagulation factor IX" GeneID="2158" HGNC_ID="HGNC:3551" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>Xq27.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="139530739" stop="139563459" display_start="139530739" display_stop="139563459" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="138612894" stop="138645616" display_start="138612894" display_stop="138645616" Strand="+" />
          </Location>
          <OMIM>300746</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=F9">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=F9">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>F9, EX2-8DEL</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq27.1-q27.2</CytogeneticLocation>
      </Location>
      <OtherNameList>
        <Name>F9, EX2-8DEL</Name>
        <Name>EX2-8DEL</Name>
      </OtherNameList>
      <XRefList>
        <XRef Type="Allelic variant" ID="300746.0075" DB="OMIM" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="F9, EX2-8DEL AND Hereditary factor IX deficiency disease" Accession="RCV000011377" Version="5">
        <ClassifiedConditionList TraitSetID="2993">
          <ClassifiedCondition DB="MedGen" ID="C0008533">Hereditary factor IX deficiency disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2017-10-09" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2017-10-09" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-10-12" MostRecentSubmission="2017-10-12">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">2472424</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2993" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2027" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">F9 DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="306900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Christmas disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Factor IX deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HEM B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PLASMA THROMBOPLASTIN COMPONENT DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="306900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary factor IX deficiency disease</ElementValue>
                <XRef ID="Hemophilia+B/3315" DB="Genetic Alliance" />
                <XRef ID="41788008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemophilia B</ElementValue>
                <XRef ID="MONDO:0010604" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HEMB</ElementValue>
                <XRef Type="MIM" ID="306900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing. The age of diagnosis and frequency of bleeding episodes are related to the level of factor IX clotting activity. In individuals with severe hemophilia B, spontaneous joint or deep-muscle bleeding is the most frequent sign. Individuals with severe hemophilia B are usually diagnosed during the first two years of life; without prophylactic treatment, they may average up to two to five spontaneous bleeding episodes each month. Individuals with moderate hemophilia B seldom have spontaneous bleeding; however, they do have prolonged or delayed oozing after relatively minor trauma and are usually diagnosed before age five to six years; the frequency of bleeding episodes varies from once a month to once a year. Individuals with mild hemophilia B do not have spontaneous bleeding episodes; however, without pre- and postoperative treatment, abnormal bleeding occurs with surgery or tooth extractions; the frequency of bleeding may vary from once a year to once every ten years. Individuals with mild hemophilia B are often not diagnosed until later in life. In any individual with hemophilia B, bleeding episodes may be more frequent in childhood and adolescence than in adulthood. Approximately 30% of heterozygous females have factor IX clotting activity lower than 40% and are at risk for bleeding (even if the affected family member has mild hemophilia B), although symptoms are usually mild. After major trauma or invasive procedures, prolonged or excessive bleeding usually occurs, regardless of severity.</Attribute>
                <XRef ID="NBK1495" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8732" />
                <XRef ID="8732" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301668</ID>
                <ID Source="BookShelf">NBK1495</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2012">
                <ID Source="PubMed">22274582</ID>
              </Citation>
              <Citation Type="general" Abbrev="UKHCDO, 2013">
                <ID Source="PubMed">23157203</ID>
              </Citation>
              <XRef ID="98879" DB="Orphanet" />
              <XRef ID="C0008533" DB="MedGen" />
              <XRef ID="D002836" DB="MeSH" />
              <XRef ID="MONDO:0010604" DB="MONDO" />
              <XRef Type="MIM" ID="306900" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="31609" SubmissionDate="2017-10-09" DateLastUpdated="2017-10-12" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300746.0075_HEMOPHILIA B" title="F9, EX2-8DEL_HEMOPHILIA B" />
        <ClinVarAccession Accession="SCV000031609" DateUpdated="2017-10-12" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-10-09">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Information was provided by Chen and Thompson (1989). The hemophilia (306900) was severe and was associated with serum inhibitors.</Attribute>
              <Citation>
                <ID Source="PubMed">2472424</ID>
              </Citation>
              <XRef DB="OMIM" ID="306900" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="F9" />
          </GeneList>
          <Name>F9, EX2-8DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">EX2-8DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300746.0075" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">HEMOPHILIA B</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="31609" TraitType="Disease" MappingType="Name" MappingValue="HEMOPHILIA B" MappingRef="Preferred">
        <MedGen CUI="C0008533" Name="Hereditary factor IX deficiency disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

